Given that Greece is still one of the countries with the highest smoking rates worldwide, Olzak emphasized the need for a practical smoking cessation plan. He emphasized that e-cigarettes and heated tobacco products align with this approach.
As cited by Ekathimerini, he did acknowledge that these products "are not without risk and can be addictive," but he rightly added that they are a "better choice" compared to continuing to smoke and using traditional cigarettes. Of course, numerous studies have already proven this point.
BAT, a competitor of PMI, conducted a randomized controlled study, titled "Exploring the Continuity of Smoking Cessation-Related Exposure When Smokers Switch to Heated Tobacco Products or E-Cigarettes among Healthy Participants", aimed at understanding the risks associated with using e-cigarettes. Researchers tracked a total of 148 healthy smokers who were randomly assigned to either continue smoking, switch to BAT's Glo HTP or prototype EC, or quit smoking completely for 5 days after a baseline period of 2 days. The researchers continued to collect respiratory and 24-hour urine samples for analysis of exposure biomarkers (BoE).
According to compiled data, after a conversion period of five days, the level of the Bank of England using Glo or prototype EC has significantly declined compared to the baseline. Consistent with previous research results, researchers found that among those exposed to a continuous spectrum, the BoE levels were lowest in non-smokers who completely quit nicotine, followed by those who switched to EC, and then those who switched to Glo.
Especially for heated tobacco product IQOS, which is used by 21 million people worldwide and 360,000 people in Greece, harmful chemical levels have been reduced by up to 95% on average.
Meanwhile, when asked about PMI's plans to expand into the health and healthcare sectors, Olzak stated that it is a natural evolution for tobacco companies. "This is a natural evolution for PMI to further transform our business into a broader lifestyle, consumer health, and healthcare company in the future. This evolution not only fulfills our commitment to achieving a smoke-free future, but also enables the development and commercialization of scientifically proven products and solutions to meet unmet consumer and patient needs.
He added that the market is already prepared for these changes. "The market for health and wellness products is huge and continually growing. We have several key areas in our pipeline. For consumer and over-the-counter healthcare products, we have initiatives focused on attention, sleep, energy, pain, and calmness. In the healthcare field, we believe there is still unmet demand for fast and effective treatment of cardiovascular diseases such as heart attacks, and neurological conditions such as migraines can be addressed through innovative solutions. We have recently accelerated this part of our strategy through the acquisition of innovators in inhalation delivery solutions provider Vectura and leading developer and manufacturer of innovative drugs and health products based on oral and buccal delivery systems Fertin," said Orzack.
According to Alzack, in addition to current efforts to prevent people from starting smoking and to help them quit, providing smokeless alternatives for consenting adults who choose to continue smoking can also have a positive impact on public health. In this context, he is calling on authorities, policy makers, and public health organizations to take appropriate action.
Statement:
This article compiles information obtained from third-party sources for the purpose of industry exchange and learning.
This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the truthfulness or accuracy of the article's content. The translation of this article is only intended for industry communication and research.
Due to limitations in the translation process, the translated article may not fully express the same meaning as the original. Please refer to the original text for accuracy.
In regards to any domestic, Hong Kong, Macao, Taiwan, or foreign affairs, 2FIRSTS maintains complete alignment with the Chinese government.
The copyright of the compiled information belongs to the original media and authors. If there is any infringement, please contact us for deletion.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
